{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:48:59Z","timestamp":1781617739179,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00054"],"award-info":[{"award-number":["PI21\/00054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["9039-00015 B"],"award-info":[{"award-number":["9039-00015 B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejphar.2022.174998","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T19:57:07Z","timestamp":1651867027000},"page":"174998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach"],"prefix":"10.1016","volume":"925","author":[{"given":"Rasmus R.","family":"Mikkelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malthe P.","family":"Hundahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Torp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Kjolby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens M.","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-397X","authenticated-orcid":false,"given":"Tue W.","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.174998_bib1","doi-asserted-by":"crossref","first-page":"735150","DOI":"10.3389\/fmed.2021.735150","article-title":"Psoriatic arthritis and metabolic syndrome: is there a role for disease modifying anti-rheumatic drugs?","volume":"8","author":"Atzeni","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.174998_bib3","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.atherosclerosis.2007.04.053","article-title":"C-reactive protein and atherogenesis: from fatty streak to clinical event","volume":"195","author":"Bisoendial","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2022.174998_bib4","doi-asserted-by":"crossref","first-page":"102731","DOI":"10.1016\/j.autrev.2020.102731","article-title":"Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment","volume":"20","author":"Br\u00fcner","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2022.174998_bib5","series-title":"Sulfasalazine, StatPearls. StatPearls Publishing Copyright \u00a9 2021","author":"Choi","year":"2021"},{"key":"10.1016\/j.ejphar.2022.174998_bib6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2016.07.768","article-title":"Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance","volume":"68","author":"Choudhury","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2022.174998_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.174998_bib8","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/dom.13702","article-title":"Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial","volume":"21","author":"Demidowich","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2022.174998_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000088261","article-title":"Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes","volume":"42","author":"Dominguez","year":"2005","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.ejphar.2022.174998_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2022.174998_bib11","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2022.174998_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8227(01)00325-4","article-title":"The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas\u2013a randomized trial","volume":"55","author":"Gerstein","year":"2002","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2022.174998_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","article-title":"Inflammation and cardiovascular disease: from pathogenesis to therapeutic target","volume":"16","author":"Golia","year":"2014","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.ejphar.2022.174998_bib14","doi-asserted-by":"crossref","first-page":"22975","DOI":"10.1074\/jbc.272.37.22975","article-title":"Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs","volume":"272","author":"Hajjar","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.174998_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.diabet.2013.07.003","article-title":"Impact of interleukin-1\u03b2 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial","volume":"39","author":"Hensen","year":"2013","journal-title":"Diabetes Metab."},{"issue":"67 Suppl. l","key":"10.1016\/j.ejphar.2022.174998_bib16","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1055\/s-2005-858252","article-title":"Inflammation and type 2 diabetes: results from KORA Augsburg","volume":"1","author":"Herder","year":"2005","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.ejphar.2022.174998_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/1753-0407.12989","article-title":"Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: a pilot study","volume":"12","author":"Hsia","year":"2020","journal-title":"J. Diabetes"},{"key":"10.1016\/j.ejphar.2022.174998_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/db18-202-LB","article-title":"2018. Global prevalence of type 2 diabetes over the next ten years","volume":"67","author":"Kaiser","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2022.174998_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2019.01.054","article-title":"Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease","volume":"281","author":"Kajikawa","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2022.174998_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2022.174998_bib24","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2013Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2022.174998_bib26","doi-asserted-by":"crossref","first-page":"619257","DOI":"10.3389\/fimmu.2020.619257","article-title":"IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives","volume":"11","author":"Malcova","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2022.174998_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.det.2013.04.006","article-title":"A metabolic autoinflammatory disease","volume":"31","author":"Mandrup-Poulsen","year":"2013","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.ejphar.2022.174998_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome","volume":"4","author":"Mart\u00ednez","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2022.174998_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.autrev.2018.06.001","article-title":"Mechanistic immunological based classification of rheumatoid arthritis","volume":"17","author":"McGonagle","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2022.174998_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.ejphar.2022.174998_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.174998_bib33","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2022.174998_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","article-title":"Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase","volume":"76","author":"M\u00fcller-Calleja","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.174998_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1074248413499972","article-title":"Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease","volume":"19","author":"Nidorf","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174998_bib37","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2018.11.016","article-title":"Why colchicine should Be considered for secondary prevention of atherosclerosis: an overview","volume":"41","author":"Nidorf","year":"2019","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174998_bib39","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.clinthera.2014.08.004","article-title":"Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus","volume":"36","author":"Noe","year":"2014","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174998_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2022.174998_bib41","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1185\/03007995.2014.909393","article-title":"Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone","volume":"30","author":"Pareek","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2022.174998_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2022.174998_bib43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.7326\/0003-4819-112-9-678","article-title":"Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?","volume":"112","author":"Quatraro","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib44","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.174998_bib45","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib47","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2022.174998_bib48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1\u03b2 antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial","volume":"14","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2022.174998_bib49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1358863X19859072","article-title":"A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease","volume":"24","author":"Russell","year":"2019","journal-title":"Vasc. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib51","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2022.174998_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.174998_bib54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejphar.2022.174998_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.174998_bib57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study","volume":"52","author":"Spranger","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2022.174998_bib58","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3874","article-title":"Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance","volume":"14","author":"Stagakis","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejphar.2022.174998_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1358863X12440117","article-title":"Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease","volume":"17","author":"Tabit","year":"2012","journal-title":"Vasc. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib61","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174998_bib62","doi-asserted-by":"crossref","first-page":"102829","DOI":"10.1016\/j.autrev.2021.102829","article-title":"Vasculitis therapy refines vasculitis mechanistic classification","volume":"20","author":"Torp","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2022.174998_bib63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a ct coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imag."},{"key":"10.1016\/j.ejphar.2022.174998_bib64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejphar.2022.174998_bib66","author":"World Health Organization"},{"key":"10.1016\/j.ejphar.2022.174998_bib67","author":"World Health Organization"},{"key":"10.1016\/j.ejphar.2022.174998_bib68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat. Immunol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992200259X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992200259X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:05:45Z","timestamp":1757977545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992200259X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":61,"alternative-id":["S001429992200259X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174998","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174998"}}